Last reviewed · How we verify
dual anti-platelet therapy 3months or less
dual anti-platelet therapy 3months or less is a Small molecule drug developed by Yonsei University. It is currently in Phase 1 development.
At a glance
| Generic name | dual anti-platelet therapy 3months or less |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dual anti-platelet therapy 3months or less CI brief — competitive landscape report
- dual anti-platelet therapy 3months or less updates RSS · CI watch RSS
- Yonsei University portfolio CI
Frequently asked questions about dual anti-platelet therapy 3months or less
What is dual anti-platelet therapy 3months or less?
dual anti-platelet therapy 3months or less is a Small molecule drug developed by Yonsei University.
Who makes dual anti-platelet therapy 3months or less?
dual anti-platelet therapy 3months or less is developed by Yonsei University (see full Yonsei University pipeline at /company/yonsei-university).
What development phase is dual anti-platelet therapy 3months or less in?
dual anti-platelet therapy 3months or less is in Phase 1.